Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand

Chongmelaxme B 1 , Phisalprapa P 2 , Manthaisong R 3 , Dilokthornsakul P 4 , Chaiyakunapruk N 5

Affiliations 

  • 1 Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, 65000, Phitsanulok, Thailand
  • 2 Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 3 Clinical Pharmacy Research Unit, Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Mahasarakham, Thailand
  • 4 Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, 65000, Phitsanulok, Thailand. piyamethd@gmail.com
  • 5 Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, 65000, Phitsanulok, Thailand. nathorn.chaiyakunapruk@monash.edu
Pharmacoeconomics, 2019 Feb;37(2):291.
PMID: 30547370 DOI: 10.1007/s40273-018-0754-y

Abstract

Weight Reduction is Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications